[1] Schmidtko A, Lötsch J, Freynhagen R, et al. Ziconotide for treatment of severe chronic pain[J]. Lancet, 2010, 375(9725): 1569-1577. [2] Kim SH, Chung JM. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat [J]. Pain, 1992, 50(3): 355- 363. [3] Chaplan SR,Bach FW, Prel JW, et al.Quantitative assessment of tactile allodynia in the rat paw[J]. J Neurosci Meth,1994,53(1):55-63. [4] Hama A, Sagen J. Antinociceptive effects of the marine snail peptides conantokin-G and conotoxin MVIIA alone and in combination in rat models of pain[J]. Neuropharmacology, 2009,56(2):556-563. [5] 史学莲, 刘小立. 齐考诺肽 (ziconotide)——一种非阿片类镇痛药物[J]. 实用疼痛学杂志, 2010,6(4): 298-301. [6] Staats PS, Yearwood T, CharapataSG, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: Arandomized controlled trial [J]. JAMA, 2004, 291(1): 63-70. [7] Alicino I, Giglio M, Manca F, et al. Intrathecal combination of ziconotide and morphine for refractory cancer pain: A rapidly acting and effective choice[J]. Pain, 2012, 153(1): 245-249. [8] Pope JE, Deer TR. Ziconotide: a clinical update and pharmacologic review[J]. Expert Opin Pharmacother, 2013, 14(7):957-966. [9] 刘国凯, 黄宇光, 罗爱伦. 神经病理性疼痛动物模型及其评价[J]. 中国临床药理学与治疗学, 2005, 10(6): 601-603. [10] Bowersox SS, Gadbois T, Singh T, et al. Selective N-type neuronal voltage-sensitive calcium channel blocker, SNX-III, produces spinal antinociception in rat models of acute,persistent and neuropathic pain[J].JPET,1996,279(3):1243-1249. |